https://www.nasdaq.com/press-release/addex-raises-%2410.0-million-in-equity-financing-2021-12-17
https://www.nasdaq.com/press-release/addex-raises-%2410.0-million-in-equity-financing-2021-12-17-0
https://www.nasdaq.com/press-release/addex-provides-year-end-pipeline-development-update-2021-12-15-0
https://www.nasdaq.com/press-release/addex-provides-year-end-pipeline-development-update-2021-12-15
https://www.nasdaq.com/press-release/addex-to-present-at-the-virtual-german-equity-forum-2021-11-18
https://www.nasdaq.com/press-release/addex-strategic-partner-successfully-completes-phase-1-in-japan-with-adx71149-2021-11
https://www.nasdaq.com/press-release/addex-to-present-at-the-h.c.-wainwright-7th-annual-israel-virtual-conference-2021-11
https://www.nasdaq.com/press-release/addex-strategic-partner-successfully-completes-phase-1-in-japan-with-adx71149-2021-0
https://www.nasdaq.com/press-release/addex-reports-q3-2021-financial-results-and-provides-corporate-update-2021-11-04-0
https://www.nasdaq.com/press-release/addex-reports-q3-2021-financial-results-and-provides-corporate-update-2021-11-04
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-q3-2021-financial-results-and-host-conference-call-on
https://www.nasdaq.com/press-release/addex-to-present-at-the-investors-day-hosted-by-voxia-communication-2021-10-06
https://www.nasdaq.com/press-release/addex-to-present-at-the-10th-international-meeting-on-metabotropic-glutamate
https://www.nasdaq.com/press-release/addex-to-present-at-the-cantor-global-healthcare-2021-conference-2021-09-29
https://www.nasdaq.com/press-release/addex-therapeutics-initiates-phase-2-clinical-study-with-dipraglurant-in-0
https://www.nasdaq.com/press-release/addex-therapeutics-initiates-phase-2-clinical-study-with-dipraglurant-in
https://www.nasdaq.com/press-release/cmta-and-addex-therapeutics-enter-collaboration-to-advance-gaba-b-pam-as-potential
https://www.nasdaq.com/press-release/cmta-and-addex-therapeutics-enter-collaboration-to-advance-gaba-b-pam-as-potential-0
https://www.nasdaq.com/press-release/addex-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment-conference-2021
https://www.nasdaq.com/press-release/addex-to-present-at-the-swiss-biotech-day-2021-09-02
https://www.nasdaq.com/press-release/addex-reports-2021-half-year-and-second-quarter-financial-results-and-provides
https://www.nasdaq.com/press-release/addex-reports-2021-half-year-and-second-quarter-financial-results-and-provides-0
https://www.nasdaq.com/press-release/addex-appoints-seasoned-pharma-drug-researcher-mikhail-kalinichev-as-head-of
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-half-year-2021-financial-results-and-host-conference
https://www.nasdaq.com/press-release/addex-appoints-seasoned-pharma-drug-researcher-mikhail-kalinichev-as-head-of-0
https://www.nasdaq.com/press-release/addex-and-indivior-extend-research-collaboration-on-gabab-positive-allosteric
https://www.nasdaq.com/press-release/addex-and-indivior-extend-research-collaboration-on-gabab-positive-allosteric-0
https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-present-at-access-to-giving-virtual-conference-on-july-14-2021
https://www.nasdaq.com/press-release/addex-therapeutics-to-present-at-access-to-giving-virtual-conference-on-july-14-0
https://www.nasdaq.com/press-release/addex-stanford-university-and-university-of-copenhagen-publish-mglu2-structure-in
https://www.nasdaq.com/press-release/addex-stanford-university-and-university-of-copenhagen-publish-mglu2-structure-in-0
https://www.nasdaq.com/press-release/addex-establishes-at-the-market-ads-equity-sale-program-2021-06-30
https://www.nasdaq.com/press-release/addex-establishes-at-the-market-ads-equity-sale-program-2021-06-30-0
https://www.nasdaq.com/press-release/addex-therapeutics-initiates-pivotal-phase-2b-3-study-with-dipraglurant-for
https://www.nasdaq.com/press-release/addex-therapeutics-initiates-pivotal-phase-2b-3-study-with-dipraglurant-for
https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july
https://www.nasdaq.com/press-release/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-2021-06-17-0
https://www.nasdaq.com/press-release/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-2021-06-17
https://www.nasdaq.com/press-release/addex-starts-phase-2-clinical-study-of-adx71149-for-epilepsy-2021-06-07
https://www.nasdaq.com/press-release/addex-starts-phase-2-clinical-study-of-adx71149-for-epilepsy-2021-06-07-0
https://www.nasdaq.com/press-release/addex-to-participate-at-the-benchmark-company-healthcare-house-call-conference-2021
https://www.nasdaq.com/press-release/addex-to-participate-at-the-benchmark-company-healthcare-house-call-conference-2021-0
https://www.nasdaq.com/press-release/addexs-dipraglurant-restores-synaptic-plasticity-in-models-of-dystonia-2021-05-17-0
https://www.nasdaq.com/press-release/addexs-dipraglurant-restores-synaptic-plasticity-in-models-of-dystonia-2021-05-17
https://www.nasdaq.com/press-release/addex-convenes-annual-general-meeting-2021-2021-05-14-0
https://www.nasdaq.com/press-release/addex-convenes-annual-general-meeting-2021-2021-05-14
https://www.nasdaq.com/press-release/addex-reports-q1-2021-financial-results-and-provides-corporate-update-2021-05-05-0
https://www.nasdaq.com/press-release/addex-reports-q1-2021-financial-results-and-provides-corporate-update-2021-05-05
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-q1-2021-financial-results-and-host-conference-call-on
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-q1-2021-financial-results-and-host-conference-call-on-0
https://www.nasdaq.com/press-release/addex-to-participate-at-the-4k-annual-neuroscience-innovation-forum-2021-04-26
https://www.nasdaq.com/press-release/addex-to-participate-at-the-4k-annual-neuroscience-innovation-forum-2021-04-26-0
https://www.nasdaq.com/press-release/addex-increases-issued-share-capital-to-create-treasury-shares-2021-04-26-0
https://www.nasdaq.com/press-release/addex-increases-issued-share-capital-to-create-treasury-shares-2021-04-26
https://www.nasdaq.com/press-release/addex-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-2021-04-0
https://www.nasdaq.com/press-release/addex-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-2021-04-13
https://www.nasdaq.com/press-release/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange
https://www.nasdaq.com/press-release/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-0
https://www.nasdaq.com/press-release/addex-reports-full-year-2020-financial-results-and-provides-corporate-update-2021-03
https://www.nasdaq.com/press-release/addex-reports-full-year-2020-financial-results-and-provides-corporate-update-2021-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-full-year-2020-financial-results-and-host-conference-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-full-year-2020-financial-results-and-host-conference
https://www.nasdaq.com/press-release/addex-to-present-at-the-h.c.-wainwright-global-life-sciences-conference-2021-03-04
https://www.nasdaq.com/press-release/addex-to-present-at-the-h.c.-wainwright-global-life-sciences-conference-2021-03-04-0
https://www.nasdaq.com/press-release/enamine-extend-collaboration-with-prominent-swiss-biotech-2021-02-24
https://www.nasdaq.com/press-release/addex-provides-trading-update-and-completes-2020-with-strong-cash-position-of-chf18.7
https://www.nasdaq.com/press-release/addex-provides-trading-update-and-completes-2020-with-strong-cash-position-of-chf18-0
https://www.nasdaq.com/press-release/addex-gabab-positive-allosteric-modulator-demonstrates-promise-in-alcohol-use-0
https://www.nasdaq.com/press-release/addex-gabab-positive-allosteric-modulator-demonstrates-promise-in-alcohol-use
https://www.nasdaq.com/press-release/addex-adx71149-receives-ind-approval-to-start-a-phase-2a-clinical-study-in-epilepsy
https://www.nasdaq.com/press-release/addex-adx71149-receives-ind-approval-to-start-a-phase-2a-clinical-study-in-epilepsy-0
https://www.nasdaq.com/press-release/addex-to-present-at-the-baader-helvea-swiss-equities-conference-2021-01-12
https://www.nasdaq.com/press-release/addex-to-present-at-the-baader-helvea-swiss-equities-conference-2021-01-12-0
https://www.nasdaq.com/press-release/addex-successfully-completes-%2411.5-million-capital-increase-including-full-exercise
https://www.nasdaq.com/press-release/addex-successfully-completes-%2411.5-million-capital-increase-including-full-exercise-0
https://www.nasdaq.com/press-release/addex-announces-pricing-of-%2410.0-million-global-offering-2021-01-06-0
https://www.nasdaq.com/press-release/addex-announces-pricing-of-%2410.0-million-global-offering-2021-01-06
https://www.nasdaq.com/press-release/addex-announces-filing-of-registration-statement-for-proposed-public-offering-of
https://www.nasdaq.com/press-release/addex-reports-q3-2020-financial-results-and-provides-corporate-update-2020-11-03-0
https://www.nasdaq.com/press-release/addex-reports-q3-2020-financial-results-and-provides-corporate-update-2020-11-03
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-q3-2020-financial-results-and-host-conference-call-on-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-q3-2020-financial-results-and-host-conference-call-on
https://www.nasdaq.com/press-release/addex-receives-additional-%242.8-million-from-indivior-and-extends-gabab-pam-research
https://www.nasdaq.com/press-release/addex-receives-additional-%242.8-million-from-indivior-and-extends-gabab-pam-research-0
https://www.nasdaq.com/press-release/addex-to-present-at-the-investora-conference-2020-09-23
https://www.nasdaq.com/press-release/addex-to-present-at-the-investora-conference-2020-09-23-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-participate-at-the-h.c.-wainwright-22nd-annual-global
https://www.nasdaq.com/press-release/addex-therapeutics-to-participate-at-the-h.c.-wainwright-22nd-annual-global-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-participate-at-the-biotechgate-digital-partnering-conference-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-participate-at-the-biotechgate-digital-partnering-conference
https://www.nasdaq.com/press-release/addex-and-the-sib-swiss-institute-of-bioinformatics-receive-innosuisse-grant-to-0
https://www.nasdaq.com/press-release/addex-and-the-sib-swiss-institute-of-bioinformatics-receive-innosuisse-grant-to
https://www.nasdaq.com/press-release/addex-reports-2020-half-year-financial-results-and-provides-corporate-update-2020-0
https://www.nasdaq.com/press-release/addex-reports-2020-half-year-financial-results-and-provides-corporate-update-2020-08
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-half-year-2020-financial-results-and-host-conference
https://www.nasdaq.com/press-release/addex-therapeutics-to-release-half-year-2020-financial-results-and-host-conference-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference-2020-0
https://www.nasdaq.com/press-release/addex-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference-2020
https://www.nasdaq.com/press-release/van-leeuwenhoeck-issues-updated-addex-equity-research-report-2020-07-20
